

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The monoclonal antibody INCA033989 under investigation for the management of myeloproliferative neoplasms inhibits which of the following proteins?
 - a. Thrombopoietin receptor
 - b. MDM2
 - c. Mutated JAK2
 - d. Mutated CALR
2. In a Phase I study of the BET inhibitor INCB057643 as monotherapy or in combination with ruxolitinib for patients with relapsed/refractory myelofibrosis (MF) or other myeloid neoplasms, what was reported regarding the efficacy endpoints of spleen size reduction and symptom burden improvement?
 - a. Spleen size reduction but no symptom burden improvement with the monotherapy and with the combination
 - b. Spleen size reduction and symptom burden improvement with the combination only
 - c. Spleen size reduction and symptom burden improvement with the monotherapy and with the combination
3. The Phase III ImpactMF study is evaluating imetelstat versus best available therapy in which patients with intermediate-2 or high-risk MF?
 - a. Patients with previously untreated disease
 - b. Patients with relapsed/refractory MF that is JAK inhibitor-naïve
 - c. Patients with MF that is relapsed/refractory after JAK inhibition
4. Which of the following observations was reported with navtemadlin in comparison to best available therapy in the Phase III BOREAS trial for patients with TP53 wild-type MF that was refractory to JAK inhibition?
 - a. No improvement in 35% or higher reduction in spleen volume from baseline (SVR35) or in 50% or higher reduction from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (TSS50)
 - b. Improvement in TSS50 but no improvement in SVR35
 - c. Improvement in SVR35 and TSS50
5. Interim results from an Italian observational study of ruxolitinib dosing and clinical outcomes in patients with MF in a real-world setting demonstrated which finding?
 - a. A low minority of patients (<10%) were dosed at a less-than-expected starting dose of ruxolitinib
 - b. Approximately a third of patients were dosed at a less-than-expected starting dose of ruxolitinib
 - c. The majority of patients were dosed at a less-than-expected starting dose of ruxolitinib